NCT02633852 is a Phase 4 clinical trial of Aflibercept in Diabetic Macular Edema (DME), sponsored by Hadassah Medical Organization.

Who is sponsoring NCT02633852?

NCT02633852 is sponsored by Hadassah Medical Organization.

What drugs are being tested in NCT02633852?

Interventions in NCT02633852: Aflibercept.

What condition does NCT02633852 study?

NCT02633852 studies Diabetic Macular Edema (DME).

Is NCT02633852 still recruiting?

NCT02633852 is currently completed. Last updated 14 September 2018.

Last reviewed 2018-09-14 · How we verify

NCT02633852

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Multicenter Study to Evaluate the Efficacy of Treat and Extend Regimen of Aflibercept (EYLEA) as a Second Line Treatment for Diabetic Macular Edema

Completed Phase 4 Last updated 14 September 2018

What this trial tests

Phase 4 trial testing Aflibercept in Diabetic Macular Edema (DME) in 48 participants. Completed in 6 September 2018.

Timeline

24 May 2016

Primary endpoint
28 August 2018

6 September 2018

Quick facts

Lead sponsor	Hadassah Medical Organization
Phase	Phase 4
Status	Completed
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	treatment
Enrollment	48
Start date	24 May 2016
Primary completion	28 August 2018
Estimated completion	6 September 2018

Drugs / interventions tested

Aflibercept (AFLIBERCEPT) — full drug profile →

Conditions studied

Diabetic Macular Edema (DME) — all drugs for Diabetic Macular Edema (DME) →

Sponsor

Hadassah Medical Organization — full company profile →

Who can join

18 and older, any sex, with Diabetic Macular Edema (DME). Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

A 12-month, Multicenter Study to Evaluate the Efficacy of Treat and Extend Regimen (TER) of Aflibercept (EYLEA) 2mg /0.05 ml as a Second Line Treatment for Diabetic Macular Edema - TADI Study

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

A 12-month prospective study to evaluate the efficacy of using the treat-and-extend regimen with intravitreal aflibercept as a Second-Line Treatment for Diabetic Macular Oedema (the TADI Study).
Tiosano L, Ehrlich R, Barak Y, Katz H, et al · · 2021 · cited 3× · PMID 32350452 · DOI 10.1038/s41433-020-0901-5

Verify or expand the search:

Other trials of Aflibercept

Trials testing the same drug.

NCT07496567 — A Clinical Trial of EYE201/MK-8748 in People With Macular Degeneration (MK-8748-003) · Phase 2, PHASE3 · not yet recruiting
NCT07440225 — A Clinical Trial of EYE201/MK-8748 in People With Macular Degeneration (MK-8748-002) · Phase 2, PHASE3 · recruiting
NCT07482176 — Efficacy and Safety Study of Ixoberogene Soroparvovec (Ixo-vec) in Participants With Neovascular Age-related Macular Deg · Phase 3 · recruiting
NCT06856577 — Efficacy and Safety Study of Ixoberogene Soroparvovec (Ixo-vec) in Participants With Neovascular Age-Related Macular Deg · Phase 3 · recruiting
NCT06839339 — Efficacy and Safety of AL-001 Ophthalmic Injection in Subjects with WAMD · Phase 2 · not yet recruiting

Other recruiting trials for Diabetic Macular Edema (DME)

Currently open trials in the same condition.

NCT07520045 — Biomarkers in Diabetic Retinopathy Treated With Faricimab vs Biosimilar Ranibizumab · NA · recruiting
NCT06662994 — High Dose Aflibercept in Diabetic Macular Edema in Patients With Previous Vitrectomy · Phase 4 · recruiting
NCT06957080 — A Study of 2 Doses of EYE103 Compared With Ranibizumab (0.5 mg) in Participants With DME · Phase 2, PHASE3 · active not recruiting
NCT06929143 — A Study to Learn More About the Use of Aflibercept in Routine Medical Practice in Japanese Participants With Neovascular · active not recruiting
NCT06914778 — Investigating the Metabolic and Lipidomic Profiles That Are Associated With Varying Grades of Diabetic Maculopathy and R · recruiting

Other Hadassah Medical Organization trials

Trials by the same sponsor.

NCT07430358 — Obstetric Risk Assessment & Cesarean-delivery in Labor Estimation Using Artificial Intelligence · NA · not yet recruiting
NCT07429019 — Intraoperative Bupivacaine Injection to Reduce Acute and Chronic Pain After TVT/TVT-O Surgery. Randomized Double-Blind T · NA · not yet recruiting
NCT07393568 — The Influence of Patient Use of Artificial Intelligence on Doctor-Patient Interaction and Clinical Outcomes in Endometri · not yet recruiting
NCT07333430 — Study of Naive HBI0101 CAR-T Therapy in Relapsed/Refractory Multiple Myeloma · Phase 1 · recruiting
NCT06762730 — Zoledronic Acid for the Prevention of TDF-sparing ART-induced Bone Mass Density Loss in Treatment-naive HIV Positive Ind · Phase 4 · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT02633852 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Hadassah Medical Organization
Last refreshed: 14 September 2018

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT02633852.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing